GenVec (NASDAQ: GNVC) is one of 182 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare GenVec to similar businesses based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.
This is a summary of current ratings and price targets for GenVec and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
GenVec currently has a consensus price target of $7.00, indicating a potential downside of 2.68%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 10.26%. Given GenVec’s peers stronger consensus rating and higher probable upside, analysts plainly believe GenVec has less favorable growth aspects than its peers.
Earnings and Valuation
This table compares GenVec and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|GenVec Competitors||$219.39 million||-$39.41 million||-66.52|
GenVec’s peers have higher revenue, but lower earnings than GenVec. GenVec is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
6.2% of GenVec shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 8.1% of GenVec shares are owned by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares GenVec and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
GenVec peers beat GenVec on 9 of the 11 factors compared.
GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company’s lead product candidate is CGF166. The Company’s vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.
Receive News & Ratings for GenVec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenVec and related companies with MarketBeat.com's FREE daily email newsletter.